Myelodysplasia and Naxos disease: A novel pathogenetic association? [5]

Leukemia

Volumn 16, Issue 11, 2002, Pages 2335-2337

  Polychronopoulou, S ^a   Tsatsopoulou, A ^b   Papadhimitriou, S I ^c   Panagiotou, J P ^a   Anastasakis, A ^d   Paterakis, G ^c   Anagnostou, D ^e   Protonotarios, N ^b,d   Haidas, S A ^a  

^a AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^b Yannis Protonotarios Medical Center   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^e EVANGELISMOS HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; MELPHALAN; PLAKOGLOBIN; STEROID; THYMOCYTE ANTIBODY;

ADOLESCENT; ANAMNESIS; APOPTOSIS; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; CANCER INHIBITION; CELL ADHESION; CELL JUNCTION; CLINICAL ARTICLE; CLINICAL EXAMINATION; CYTOGENETICS; DISEASE ASSOCIATION; DNA DETERMINATION; GENETIC DISORDER; GRAFT VERSUS HOST REACTION; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; LABORATORY TEST; LETTER; MYELODYSPLASTIC SYNDROME; PATHOGENESIS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0036850150     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402587     Document Type: Letter

References (8)

1. Groupe Francais de Cytogenetique Hematologique. Forty-four cases of childhood myelodysplasia with cytogenetics, documented by the Groupe Francais de Cytogenetique Hematologique. Leukemia 1997; 11: 1478-1485.
2. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, Norman M, Baboonian C, Jeffery S, McKenna WJ. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355: 2119-2124.
3. Hakimelahi S, Parker HR, Gilchrist AJ, Barry M, Li Z, Bleakley RC, Pasdar M. Plakoglobin regulates the expression of the antiapoptotic protein BCL-2. J Biol Chem 2000; 275: 10905-10911.
4. Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Zeev A. Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 1996; 133: 199-209.
5. Tsutsui J, Moriyama M, Arima N, Ohtsubo H, Tanaka H, Ozawa M. Expression of cadherin-catenin complexes in human leukemia cell lines. J Biochem (Tokyo) 1996; 120: 1034-1039.
6. Barth AI, Nathke IS, Nelson WJ. Cadherins, catenins and APC protein: interplay between cytoskeletal complexes and signalling pathways. Curr Opin Cell Biol 1997; 9: 683-690.
7. Aberle H, Bierkamp C, Torchard D, Serova O, Wagner T, Natt E, Wirsching J, Heidkamper C, Montagna M, Lynch HT, Lenoir GM, Scherer G, Feunteun J, Kemler R. The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. Proc Natl Acad Sci USA 1995; 92: 6384-6388.
8. Pantel K, Passlick B, Vogt J, Stosiek P, Angstwurm M, Seen-Hibler R, Haussinger K, Thetter O, Izbicki JR, Riethmuller G. Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J Clin Oncol 1998; 16: 1407-1413.